Shakti Ramkissoon: Labcorp finalizes Acquisition of Select Assets of Invitae

Shakti Ramkissoon, CLIA Laboratory Medical Director at Labcorp Oncology (OmniSeq), Buffalo, NY shared a post on LinkedIn:

“Exciting news, Labcorp has finalized the acquisition of select assets from Invitae, and we couldn’t be more thrilled to welcome them to the Labcorp family.

Invitae’s best-in-class hereditary cancer testing portfolio is a fantastic addition to our capabilities.

At Labcorp Oncology, our vision is clear: to become the single-source solution for patients, providers, healthcare systems, and biopharma.

We’ve been strategically building our portfolio of precision oncology testing, starting with the acquisition of OmniSeq, followed by PGD (Personal Genome Diagnostics), and now Invitae.

With these combined assets and the innovative tests and solutions currently in our developmental pipeline, we are steadily moving closer to leading the precision oncology space for both centralized testing and FDA-authorized kitted solutions for CGP testing.

When you pair this with our core oncology testing, including surgical pathology, flow cytometry, and cytogenetics, we offer comprehensive testing to support patients fighting cancer.

Additionally, our strong clinical testing portfolio, covering essential labs like CBCs, chemistry, and microbiology, ensures Labcorp is the easiest group to work with for all oncology patient testing.

In a world of fragmented testing solutions where providers often must send patient tests to multiple labs, Labcorp Oncology stands out.

Our mission is to be the single-source solution for all your oncology testing needs, ensuring you have the right information at the right time to make the best treatment decisions.

Welcome, Invitae, to our journey towards transforming oncology care”

Source: Shakti Ramkissoon/LinkedIn